Published in Cancer Biol Ther on March 18, 2003
Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol (2008) 1.17
Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation. J Biol Chem (2012) 1.16
Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol (2011) 1.11
Vasculogenic mimicry: a novel target for glioma therapy. Chin J Cancer (2013) 0.95
A Matrigel-based tube formation assay to assess the vasculogenic activity of tumor cells. J Vis Exp (2011) 0.92
Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J Cell Biochem (2008) 0.91
Study on the characteristics of contrast-enhanced ultrasound and its utility in assessing the microvessel density in ovarian tumors or tumor-like lesions. Int J Biol Sci (2011) 0.90
A pilot histomorphology and hemodynamic of vasculogenic mimicry in gallbladder carcinomas in vivo and in vitro. J Exp Clin Cancer Res (2011) 0.90
Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg (2010) 0.89
Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One (2013) 0.87
Transforming growth factor-β is required for vasculogenic mimicry formation in glioma cell line U251MG. Cancer Biol Ther (2011) 0.85
Extracellular matrix metalloproteinase inducer (EMMPRIN) expression correlates positively with active angiogenesis and negatively with basic fibroblast growth factor expression in epithelial ovarian cancer. J Cancer Res Clin Oncol (2013) 0.82
CD44 enhances tumor aggressiveness by promoting tumor cell plasticity. Oncotarget (2015) 0.82
Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets. Biomark Res (2015) 0.81
Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy. Curr Angiogenes (2012) 0.80
Mig-7 linked to vasculogenic mimicry. Am J Pathol (2007) 0.78
cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget (2016) 0.78
Galunisertib inhibits glioma vasculogenic mimicry formation induced by astrocytes. Sci Rep (2016) 0.76
Prognostic biomarkers in ovarian cancer. Cancer Biomark (2011) 0.75
Inhibitory effects of B-cell lymphoma 2 on the vasculogenic mimicry of hypoxic human glioma cells. Exp Ther Med (2014) 0.75
The merits of vascular targeting for gynecologic malignancies. Curr Oncol Rep (2005) 0.75
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget (2017) 0.75
Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo. Oncol Lett (2016) 0.75
Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma. Transl Oncol (2017) 0.75
Structural and functional identification of vasculogenic mimicry in vitro. Sci Rep (2017) 0.75
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54
A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res (2002) 2.65
Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. Proc Natl Acad Sci U S A (2008) 2.51
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Paradoxical roles for lysyl oxidases in cancer--a prospect. J Cell Biochem (2007) 2.30
Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res (2005) 2.27
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion. Am J Pathol (2004) 2.12
Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol (2007) 1.99
Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res (2005) 1.95
Maspin regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther (2003) 1.85
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Dev Dyn (2005) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Science policy. The NIH budget in the "postdoubling" era. Science (2002) 1.74
The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res (2002) 1.71
Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc Natl Acad Sci U S A (2006) 1.67
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
Tumor cell vasculogenic mimicry: from controversy to therapeutic promise. Am J Pathol (2012) 1.58
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma. Cancer Biol Ther (2006) 1.57
Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res (2002) 1.57
EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer (2007) 1.57
Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther (2010) 1.55
Biological functions of maspin. J Cell Physiol (2006) 1.54
Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res (2012) 1.52
Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res (2003) 1.50
Molecular determinants of human uveal melanoma invasion and metastasis. Clin Exp Metastasis (2002) 1.50
Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res (2010) 1.49
Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst (2004) 1.49
Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biol Ther (2005) 1.49
Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia. Cancer Res (2005) 1.49
Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem (2005) 1.44
Differential regulation of EphA2 in normal and malignant cells. Am J Pathol (2003) 1.43
Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem (2008) 1.41
p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Ther (2002) 1.41
VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther (2006) 1.41
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther (2004) 1.40
Transendothelial function of human metastatic melanoma cells: role of the microenvironment in cell-fate determination. Cancer Res (2002) 1.36
ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia (2010) 1.36
Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry. Cancer Res (2003) 1.35
Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate (2011) 1.34
Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. Crit Rev Oncol Hematol (2002) 1.32
Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate (2002) 1.32
Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Res (2009) 1.30
A three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells (2005) 1.26
Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol (2008) 1.22
Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics (2009) 1.22
Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res (2005) 1.22
Maspin: molecular mechanisms and therapeutic implications. Cancer Metastasis Rev (2012) 1.21
Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res (2012) 1.21
Potential for cripto-1 in defining stem cell-like characteristics in human malignant melanoma. Cell Cycle (2008) 1.20
Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol (2004) 1.20
Influence of the microenvironment on melanoma cell fate determination and phenotype. Cancer Res (2006) 1.18
Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn (2008) 1.18
A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS One (2012) 1.17
Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn (2007) 1.16
Severe feto-placental abnormalities precede the onset of hypertension and proteinuria in a mouse model of preeclampsia. Biol Reprod (2006) 1.12
A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. J Biol Chem (2006) 1.08
Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest (2011) 1.07
Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Res (2005) 1.06
Lysyl oxidase regulates actin filament formation through the p130(Cas)/Crk/DOCK180 signaling complex. J Cell Biochem (2006) 1.06
Targeting Nodal in malignant melanoma cells. Expert Opin Ther Targets (2007) 1.05
Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia (2004) 1.05
Emerging roles of nodal and Cripto-1: from embryogenesis to breast cancer progression. Breast Dis (2008) 1.03
IFN-gamma regulation of vacuolar pH, cathepsin D processing and autophagy in mammary epithelial cells. J Cell Biochem (2008) 1.02
Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Mol Cancer Ther (2002) 1.00
Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem (2004) 1.00
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
Conserved properties of HP1(Hsalpha). Gene (2004) 0.99
IRF6 in development and disease: a mediator of quiescence and differentiation. Cell Cycle (2008) 0.99
Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res (2008) 0.99
Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells (2010) 0.99
The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J Cell Biochem (2007) 0.97
The epigenetic influence of tumor and embryonic microenvironments: how different are they? Cancer Microenviron (2008) 0.97
Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther (2005) 0.95
Global demethylation of rat chondrosarcoma cells after treatment with 5-aza-2'-deoxycytidine results in increased tumorigenicity. PLoS One (2009) 0.95
Elucidating the function of secreted maspin: inhibiting cathepsin D-mediated matrix degradation. Cancer Res (2007) 0.94
Elevated focal adhesion kinase expression facilitates oral tumor cell invasion. Cancer (2002) 0.94
Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle (2006) 0.94
Tyrosine phosphorylation of maspin in normal mammary epithelia and breast cancer cells. Biochem Biophys Res Commun (2002) 0.93
Cancer hallmarks in induced pluripotent cells: new insights. J Cell Physiol (2010) 0.93
Genetic analysis of the 'uveal melanoma' C918 cell line reveals atypical BRAF and common KRAS mutations and single tandem repeat profile identical to the cutaneous melanoma C8161 cell line. Pigment Cell Melanoma Res (2015) 0.92
Nodal expression and detection in cancer: experience and challenges. Cancer Res (2012) 0.92
Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma. J Cell Biochem (2008) 0.91
The embryonic-like properties of aggressive human tumor cells. J Soc Gynecol Investig (2002) 0.89